The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
Sharon Osbourne was pictured with Black Sabbath star Tony Iommi after it was announced the band was reuniting for 'the ...
The new skull exhibits a long, pointed beak and a brain shape unique among all known birds previously discovered from the ...
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
1d
A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...
A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback